Navigation Links
DrugRisks Announces Yaz Center With Latest Updates on Blood Clot Warnings and Settlements
Date:5/29/2013

Chicago, IL (PRWEB) May 29, 2013

The birth control safety advocates at DrugRisks.com are announcing a new resource center for patients who have taken the contraceptives Yaz or Yasmin. The site contains warnings about the drugs’ alleged link to blood clots and compensation offered by Bayer for victims.

DrugRisks was created to give patients taking popular prescription drugs like Yaz and Yasmin the latest warnings, recalls, studies and legal news. With access to clear information, patients can discuss side effect concerns with their doctor and decide if they need legal advice.

The resource center contains studies from the British Medical Journal* and FDA** showing patients taking birth control pills containing drospirenone, like Yaz and Yasmin, may have an increased risk of developing blood clots.

With a growing number of patients filing a Yaz lawsuit alleging blood clot injuries, cases were consolidated to a special federal Multi-District Litigation court in Illinois (Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100, Southern District Illinois).

DrugRisks has also learned that the maker of Yaz and Yasmin, Bayer, has spent nearly $1 billion so far to settle around 4,800 claims alleging Yaz blood clots, and will continue to evaluate new claims for settlement on a case-by-case basis***.

Although a federal court recently opened up competition for Yaz from generics****, DrugRisks cautions patients that blood clots have been linked to the chemical drospirenone, which is used in both brand name and generic formulations.

Lawyers are still helping those affected file a claim. Anyone who suffered a blood clot, DVT, stroke or pulmonary embolism after taking Yaz or Yasmin is urged to contact the DrugRisks Center or speak with a lawyer about their legal options.

Due to the specialized nature of federal

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related medicine news :

1. DrugRisks Update: New Study Warns of Pradaxa Brain Bleeding
2. Latest Court Records Show 6% Increase In NuvaRing Lawsuits, DrugRisks Notes
3. DrugRisks Update: Latest Court Figures Show Rise In Pradaxa Lawsuits
4. DrugRisks Update: Yaz Class Action Begins in Canada as Settlements Continue in U.S.
5. DrugRisks Update: Warning Added to Pradaxa For Blood Condition
6. DrugRisks Update: Use of NuvaRing Drops Amid Injury Allegations
7. DrugRisks News Update: Bayer Loses Yaz Patent as Blood Clot Settlements Continue
8. DrugRisks Adds Update From Court Ordering Mediation of Stryker Hip Lawsuits
9. DrugRisks Update: Federal Court Schedules First Mirena Lawsuit Hearing
10. DrugRisks Legal Update: Jury to Decide Actos Cancer Trial This Week
11. DrugRisks Update: Doctor Testifies Actos Main Cause of Bladder Cancer in Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Research has been chosen by Plymouth University to be ... in April 2009 to raise awareness of, and funding ... for brain tumour patients. , A range of events ... for the charity, and members of staff and students, ... to donate, fundraise and volunteer. The involvement of the ...
(Date:8/20/2014)... Boston, MA (PRWEB) August 20, 2014 Fresh ... new jogging stroller just sprung from the starting blocks. , ... design studios, has added the Urbini Avi jogger ... for nearly a year, with a look inspired by the ... and delight fitness-minded parents. , This versatile jogger offers a ...
(Date:8/20/2014)... 20, 2014 Parents and kids across ... from summer months means buying textbooks and arranging after ... often a forgotten part of the annual re-commitment to ... the American Psychological Association, 27% of students say they ... (45%) say they are stressed by school pressures. The ...
(Date:8/20/2014)... 20, 2014 The report “Automotive ... - A Global Analysis: by Geography - Trends ... classifies and defines automotive airbag and seatbelt market ... highlights potential growth opportunities in the coming years ... market drivers, restrains, growth indicators, challenges, legislation trends, ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 B. E. ... to healthcare providers, has been retained to lead a ... Shepherd Health Care System in Hermiston, Ore. The top ... B. E. Smith has recently placed more than 900 ... Care System is a progressive, not-for-profit healthcare organization serving ...
Breaking Medicine News(10 mins):Health News:Plymouth University chooses Brain Tumour Research as official charity 2Health News:Urbini Breezes Through Summer with New Jogging Stroller 2Health News:Five Easy Steps to Help Your Child Manage Back-to-school Stress 2Health News:Five Easy Steps to Help Your Child Manage Back-to-school Stress 3Health News:Automotive Airbag Market Worth $23.6 Billion and Automotive Seat Belt Market Worth $9.0 Billion by 2019 – New Report by MarketsandMarkets 2Health News:Automotive Airbag Market Worth $23.6 Billion and Automotive Seat Belt Market Worth $9.0 Billion by 2019 – New Report by MarketsandMarkets 3Health News:Automotive Airbag Market Worth $23.6 Billion and Automotive Seat Belt Market Worth $9.0 Billion by 2019 – New Report by MarketsandMarkets 4Health News:Good Shepherd Health Care System Retains B. E. Smith to Recruit New COO 2Health News:Good Shepherd Health Care System Retains B. E. Smith to Recruit New COO 3
... doctors in hospital and general practice are being concerned about a ... that 93% of those with worries had taken some form of ... 10% of GPs and 4% of hospital doctors had taken no ... expressed concerns and even made reference to possible alcohol abuse. ...
... Calcutta Medical College and Hospital expressed their support to ... northern region of the State. West Bengal is ... ,Barring the emergency department, services in the Calcutta ... doctors and interns struck work against the central government's ...
... Dr. Michael Thun of the American Cancer Society it was found ... wee less.// On the other hand men who never smoked had ... among a million Americans. Lung cancer is by far the biggest ... this year in the United States alone. ,This report ...
... moderate exercise regimen for 30-45 minutes, performed on all weekdays ... cancer in women. Breast cancer// is the most common form ... women at some stage of their life in the Western ... achieve early detection and effective treatment, about 20 percent of ...
... scare not yet ascertained the top floors of the Melbourne ... to identify the cause of illnesses.// ,Tests on ... to establish any link as yet to the seven cases ... ,Five of these seven cases were employees who had ...
... to researchers at the University of Pennsylvania and Temple ... important role in diseases of the eye. This is ... covering the eyes.// The researchers, led by Mina ... Institute, and Marcella Macaluso, Ph.D., of the Sbarro Institute ...
Cached Medicine News:Health News:Increase In The Number Of Doctors Reporting About Their Colleagues Abilities 2Health News:Medicos Of The Calcutta Medical College Join Anti-Reservation Quota Protest 2Health News:Moderate Exercise, Key To Breast Cancer Prevention 2Health News:PAI-2 Plays a Pivotal Role in Eye Infections 2
(Date:8/20/2014)... , August 20, 2014 ... Conducted in the US  KalVista Pharmaceuticals ("KalVista"), ... edema (DME), today announces that it has begun a ... plasma kallikrein inhibitor, KVD001, for the treatment of DME. ... of the Beetham Eye Institute, Joslin Diabetes Center; Harvard ...
(Date:8/19/2014)... -- Talyst, a market leader in pharmacy automation and ... Summer Conference in Las Vegas, NV. ... products and services.   Talyst is the ... customers with a variety of software and services. Talyst ... solution, AutoSplit® Contract Pharmacy and 340B Compliance Services. AutoSplit ...
(Date:8/19/2014)... 2014 /PRNewswire-iReach/ -- ChemImage founder and CTO, Patrick ... describing an innovative diagnostic procedure for the detection of ... on Disease (SPEC) conference in Krakow, Poland ... "Development of in vitro Diagnostics for Detection of Colorectal ... the conference poster session on Tuesday, August 19, 2014 ...
Breaking Medicine Technology:KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4Talyst Exhibits at the NPPA Summer Conference 2ChemImage Scientists Present Latest Developments for in vitro Detection of Colorectal Cancer Using Raman Molecular Imaging (RMI) at International Conference Focused on Biomedical Applications of Raman Spectroscopy 2
... June 20, Actelion Ltd (SWX: ATLN) announced today ... mildly symptomatic pulmonary,arterial hypertension (PAH) patients (WHO functional ... clinical deterioration by significantly,delaying time to clinical worsening ... FC III/IV. A significant reduction in pulmonary vascular,resistance ...
... PXS; Nasdaq: PXSL) today announced that the company ... reached agreement on the phase 3,registration trial of ... The SPA process allows for FDA evaluation ... primary basis of an efficacy claim in support ...
Cached Medicine Technology:Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease 2Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease 3Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease 4Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease 5Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease 6Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial 2Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial 3
... Pump is a syringe infusion ... the administration of many intravenous ... It provides for the convenient ... and vasoactive drugs through the ...
Developed to meet the infusion needs in NICU, Anesthesia and Critical Care, the AUTO SYRINGE AS50 Infusion Pump delivers precise, controlled infusions....
Pain management can be complicated. But that doesn't mean your PCA infusion system should be. The new SYNDEO PCA Syringe Pump streamlines pain therapy with a powerful combination of intelligent desig...
The FLO-GARD 6201 Volumetric Infusion Pump and the FLO-GARD 6301 Dual-Channel Volumetric Infusion Pump are industry standard in standard set infusion pump technology....
Medicine Products: